Scholarlink

Introduction <p>Blue light (BL) induces reactive oxygen species (ROS), exerting an antimicrobial effect. This study will assess its effectiveness in women with recurrent vulvovaginal candidiasis (RVVC). </p> Methods <p>This study was designed as a controlled, randomized, double-blind clinical trial. The intervention consists of applying a BL device with a wavelength of 401 ± 5 nm to the vulvovaginal region for 21 days, with two weekly sessions of 30 minutes each. The sample will consist of 51 women aged between 18 and 40 years, diagnosed with recurrent vaginal candidiasis and in a stable relationship. Participants will be randomly allocated to one of three groups: Group II: luconazole 200 mg; Group II: inactive BL in combination with luconazole 200 mg; Group III: active BL and luconazole 200 mg. The medication will be prescribed by a physician.</p> Results <p>Participants will undergo assessments at baseline, after the first treatment, and on days 7, 14, 21, and the third day after the inal application to monitor outcomes. The primary outcome will be the absence of Candida Albicans (CA), while secondary outcomes include improvements in quality of life, sleep quality and reduction in levels of stress, anxiety and depression after treatment. Descriptive statistics and generalized models with Bonferroni post-tests will be used for intergroup comparisons, adopting p &lt; 0.05.</p> Conclusion <p>BL is expected to emerge as a potential non-pharmacological alternative for reducing Candida Albicans fungal load, improving clinical symptoms, and enhancing the quality of life of women with RVVC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Protocol for a randomized clinical trial on the efficacy of blue light emitting diode in the treatment of recurrent vulvovaginal candidiasis

  • 期刊论文

  • 发表日期：

    2025年6月5日

查看全文
  • Janaina das Graças da Silva Ramos,
  • Matheaus Oliveira da Costa,
  • João Lucas Peres dos Santos,
  • Maria Thereza Albuquerque Barbosa Cabral Micussi,
  • Guilherme Pertinni de Morais Gouveia

摘要

Introduction

Blue light (BL) induces reactive oxygen species (ROS), exerting an antimicrobial effect. This study will assess its effectiveness in women with recurrent vulvovaginal candidiasis (RVVC).

Methods

This study was designed as a controlled, randomized, double-blind clinical trial. The intervention consists of applying a BL device with a wavelength of 401 ± 5 nm to the vulvovaginal region for 21 days, with two weekly sessions of 30 minutes each. The sample will consist of 51 women aged between 18 and 40 years, diagnosed with recurrent vaginal candidiasis and in a stable relationship. Participants will be randomly allocated to one of three groups: Group II: luconazole 200 mg; Group II: inactive BL in combination with luconazole 200 mg; Group III: active BL and luconazole 200 mg. The medication will be prescribed by a physician.

Results

Participants will undergo assessments at baseline, after the first treatment, and on days 7, 14, 21, and the third day after the inal application to monitor outcomes. The primary outcome will be the absence of Candida Albicans (CA), while secondary outcomes include improvements in quality of life, sleep quality and reduction in levels of stress, anxiety and depression after treatment. Descriptive statistics and generalized models with Bonferroni post-tests will be used for intergroup comparisons, adopting p < 0.05.

Conclusion

BL is expected to emerge as a potential non-pharmacological alternative for reducing Candida Albicans fungal load, improving clinical symptoms, and enhancing the quality of life of women with RVVC.